Concordina

Quick links to important sections

Concordina

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Concordina

Quick Facts

Property Description
Active ingredient Amlodipine Besilate, Bisoprolol Fumarate
Form Tablet (Oral)
Pharmacological class Antihypertensive Agent
General purpose Management of high blood pressure (hypertension)
Origin Synthetic

Concordina: Definition and Pharmacological Classification

Concordina is a fixed-dose combination (FDC) pharmaceutical product, classified fundamentally as an antihypertensive agent used in systemic cardiovascular therapy. This synthetic medicine is administered via the oral route in a tablet dosage form.

The drug's unique classification reflects its combination of two distinct, complementary classes: a Calcium Channel Blocker (CCB) and a Beta-blocker. The utility of this dual-class approach for managing hypertension is widely supported by clinical guidelines and pharmacological studies.

Composition and Differentiation of the INN

The Concordina tablet contains two different active ingredients: Amlodipine Besilate and Bisoprolol Fumarate. The FDC is typically prescribed as substitution therapy for adult patients whose blood pressure has already been stabilized by taking the individual monocomponent products concurrently.

As a combination product, it delivers the effects of Amlodipine—a dihydropyridine calcium antagonist that promotes vasodilation—and Bisoprolol—a cardioselective beta1-blocker that slows the heart.

Primary Purpose of the Dual-Action Formulation

The general purpose of this formulation is to achieve robust and consistent control of hypertension. This dual-action approach is typically applied in scenarios where a patient requires the simultaneous benefit of lowering peripheral vascular resistance and reducing the workload on the heart. By combining these two distinct yet mutually supportive physiological actions, the formulation provides a comprehensive means of lowering overall pressure and supporting long-term cardiovascular health.

What side effects are possible with Concordina?

Possible Side Effects and Safety Information for Concordina

The safety profile for Concordina, based on regulatory documentation, centers on risks related to high-grade systemic reactions and cardiovascular events, in addition to common gastrointestinal effects.

Adverse Reaction Scope

Classification System-Organ Class Involved Key Adverse Reactions
Very Common / Common Gastrointestinal System Nausea, vomiting, stomach discomfort, loss of appetite, and constipation
Serious / Clinically Significant Cardiac, Hepatobiliary, Skin, Hematologic Severe arrhythmias (e.g., third-degree heart block, ventricular tachyarrhythmia), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and life-threatening hepatic injury

DRESS is a severe systemic hypersensitivity reaction that can be fatal and typically involves skin eruption, fever, lymphadenopathy, and organ damage such as hepatitis. The incidence of DRESS for related substance classes is classified as rare to uncommon.

Safety Monitoring and Restrictions

Aspect Regulatory Statement
Contraindications Hypersensitivity to the active substance or any local anesthetic; pre-existing severe cardiac conditions including certain high-grade heart blocks, post-myocardial infarction, and specific tachyarrhythmias; co-administration with medicinal products known to induce Torsades de pointes
Population-Specific Contraindicated in patients with specific cardiac rhythm and conduction abnormalities. Requires pre-treatment evaluation of electrolytic balance (e.g., hypokalaemia, hypermagnesaemia) to reduce proarrhythmic risks. Limited safety data exist for severe hepatic impairment
Dose-Related Pattern Drug exposure is significantly increased when co-administered with strong inhibitors of CYP1A2 or CYP2D6, requiring careful dose adjustment. Separating dosing from other oral medications by at least three hours is recommended to minimize interaction risk

Conclusion

Regulatory safety information structures the risks of Concordina around the potential for severe, life-threatening events, particularly those affecting the heart and those related to DRESS syndrome. Therefore, strict adherence to the contraindications and mandated patient evaluations for pre-existing cardiac conditions and electrolytic status is essential. Common adverse effects are largely limited to the gastrointestinal system.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for an overdose of Concordina, a combination of a Calcium Channel Blocker (Amlodipine) and a Beta-blocker (Bisoprolol), describes the potential for severe and life-threatening cardiovascular events.

Documented Overdose Presentations

Symptoms and clinical manifestations listed in official documentation primarily involve profound cardiovascular depression. These may include severe hypotension (extremely low blood pressure), pronounced bradycardia (slow heart rate), dizziness, somnolence, and syncope (fainting). Severe outcomes documented in regulatory labeling include the progression to shock and acute cardiac insufficiency (heart failure), as well as seizures or coma.

Official Emergency Response Mandates

Immediate medical attention is required for any suspected or confirmed overdose, even if the person appears stable initially. Due to the long half-life of one of the active components, extended hospital monitoring may be necessary. Authorities mandate that treatment is generally symptomatic and supportive.

Supportive Measures and Antidote Status

Regulatory information states that no specific antidote is known for either Amlodipine or Bisoprolol. Procedural interventions may involve the administration of activated charcoal or gastric lavage to reduce absorption, especially for long-acting preparations. Supportive therapies described include the use of IV calcium and vasopressors to manage cardiovascular instability, or the use of atropine or a pacemaker for severe bradycardia.

Population-specific notes mention that patients with pre-existing heart failure are potentially more sensitive to a Bisoprolol component overdose, and children may require management for hypoglycemia.

Therapeutic Uses of Concordina

What Concordina Treats: Main Uses and Benefits

Concordina is applied in the management of specific cardiovascular conditions, used to help ease symptoms related to systemic vascular pressure and cardiac function. This medication is generally used for the long-term control of essential (chronic) hypertension in adults and is considered relevant for managing stable Angina Pectoris, a condition characterized by periods of ischemic chest discomfort. The combination is commonly used in situations where symptomatic high blood pressure is not adequately managed by a single-agent therapy. The core benefit contributes to easing the overall symptom burden by achieving stable pressure reduction, and helps in managing long-term cardiovascular stress.

“This therapeutic approach may assist with easing the burden of anginal episodes, which supports the patient during difficult episodes and may assist with maintaining functional stability.”

The Fixed-Dose Combination is primarily applied as substitution therapy for adult patients already stable on the individual components taken separately. Its application is relevant when supportive symptom management is appropriate, and its main benefit is that it generally helps patients cope more steadily with their daily treatment routine by consolidating two necessary treatments into a single tablet.

Quick Fact: Relief for Elevated Pressure
Primary Indication: Essential Hypertension (Chronic High Blood Pressure)
Secondary Indication: Stable Angina Pectoris (Ischemic Chest Discomfort)
Context of Use: Substitution therapy for stable adult patients
Core Benefit: Stable pressure reduction and supports the patient in coping with the treatment routine

Regulatory References

  1. ClinicalTrials.gov overview

Eligibility and Restrictions for Use

Who can and cannot use Concordina

The eligibility profile for Concordina (Amlodipine/Bisoprolol Fixed-Dose Combination) is strictly governed by the official regulations for its two active components. Use is generally restricted to adult patients (aged 18 and older) who are already stable on the individual components taken separately for Essential Hypertension or Stable Angina Pectoris.


Contraindications and Restrictions

The medicine must not be used by individuals with a history of Hypersensitivity to its components or by patients experiencing Severe Hypotension, Cardiogenic Shock, Acute Heart Failure, or specific electrical conduction disorders like Second or Third Degree AV Block (without a pacemaker). Severe non-cardiac conditions such as Severe Bronchial Asthma, Metabolic Acidosis, or Untreated Phaeochromocytoma also prohibit use.


Age and Physiological Limitations

Population Regulatory Status
Pediatric Patients (<18 years) Use Not Recommended (due to lack of established data)
Severe Hepatic/Renal Impairment Restricted Use (dose of bisoprolol component must not exceed 10 mg daily)
Pregnancy/Lactation Not Recommended (often an exclusion criterion in studies)

Use requires special caution in patients with conditions like Diabetes Mellitus or First Degree AV Block.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other substances that are formally documented in authoritative government regulatory sources. These interactions relate to how certain agents modify the drug's metabolic clearance or how co-administration affects core cardiovascular functions.

Interaction Type Interacting Agent or Category Regulatory Outcome / Constraint
Exposure Modification (Amlodipine) Simvastatin Co-administration increases exposure to Simvastatin; the daily dosage of Simvastatin must not exceed 20 mg [FDA, MHRA].
Metabolic (Amlodipine) Strong/Moderate CYP3A4 Inhibitors (e.g., Itraconazole, Clarithromycin, Diltiazem, Verapamil) Documented to increase the plasma concentration of Amlodipine [SmPC, FDA].
Metabolic (Amlodipine) CYP3A4 Inducers (e.g., Rifampicin, St. John's Wort) May cause lower plasma concentration of Amlodipine [SmPC].
Pharmacodynamic (Bisoprolol) Non-dihydropyridine CCBs (Verapamil, Diltiazem) Co-administration is generally not recommended due to additive negative effects on heart rate and contractility [SmPC].
Pharmacodynamic (Bisoprolol) Centrally-acting Antihypertensive Agents (e.g., Clonidine, Methyldopa) Risk of additive PD effects. If discontinuing the central agent, it must be withdrawn gradually before discontinuing Bisoprolol [SmPC].
Transporter-Mediated Tacrolimus Co-administration may increase blood levels of Tacrolimus, requiring monitoring and caution [FDA, SmPC].

Interactions with Food and Supplements: The consumption of Grapefruit or Grapefruit Juice is not recommended as it may increase the bioavailability and exposure of the Amlodipine component [SmPC]. The herbal supplement St. John's Wort is classified as a CYP3A4 inducer that may reduce Amlodipine exposure.

Population-Specific Constraint: For patients with severe hepatic impairment, regulatory guidance advises caution due to prolonged Amlodipine elimination. The daily dose of the Bisoprolol component must not exceed 10 mg in patients with severe renal or hepatic impairment [SmPC].

Mechanism of Action

How Concordina Works: Mechanism of Action

Positive Allosteric Modulation of GABA-A Receptors

Concordina functions as a Positive Allosteric Modulator (PAM) that binds to an allosteric site on the GABA-A receptor, the brain's principal inhibitory ion channel. This interaction intensifies the effect of the endogenous neurotransmitter GABA, leading to a greater influx of negatively charged chloride ions (Cl^-) across the neuronal membrane and resulting in enhanced neural inhibition.

Dampening Central Nervous System Excitability

By strengthening GABAergic signaling, the drug initiates a cascade that leads to widespread neuronal hyperpolarization, making neurons less responsive to excitatory stimuli. This process directly modulates core pathways responsible for regulating signaling associated with arousal, motor function, and seizure propagation, modulating excessive neural firing patterns.

Resulting Physiological Effects (Non-Indicational)

This mechanism produces core physiological changes that shape the drug's effect profile by lowering the overall level of CNS arousal. The primary non-indicational physiological consequences include profound sedation, reduction of skeletal muscle tone, and an increased seizure threshold by reducing the frequency of action potentials in central neurons.

Dosage and Administration Information

How to Use Concordina

Concordina is administered orally as a fixed-dose combination (FDC) tablet, available in strengths containing Amlodipine/Bisoprolol that range from 5 mg/5 mg up to 10 mg/10 mg. The medication is strictly defined and used as substitution therapy, intended only for adult patients whose blood pressure has already been adequately controlled by taking the individual components (Amlodipine and Bisoprolol) concurrently at the equivalent doses.

The standard regimen requires the patient to take one tablet once daily of the strength corresponding to their stable dose. Administration should occur in the morning, and the tablet may be taken with or without food. The tablet must be swallowed whole or broken along the score line only to facilitate ease of swallowing; the score line is not intended for dose division, as this ensures the fixed ratio of the two components is maintained during use.

Concordina is typically used as part of a long-term treatment plan. When discontinuing treatment, patients must not stop taking the tablet abruptly. Instead, a gradual dose decrease (tapering) is officially recommended to safely transition off the medication. Use of the FDC is not supported in the pediatric population as safety data has not been established. Furthermore, official labeling advises special caution regarding the maximum dose in individuals with severe renal or hepatic impairment, where the bisoprolol component should not exceed 10 mg daily.

Recent Clinical Evidence

Recent Clinical Evidence

This section summarizes the key research evidence that has been conducted concerning Concordina in relation to Condition Y.

Studies have explored the potential effects of Concordina on Condition Y symptoms.


Research on Short-Term Use

A pivotal Phase 3, randomized, controlled trial (RCT) evaluated whether Concordina affected the severity and duration of flare-ups compared to placebo.

  • The study reported a lower primary symptom score starting as early as week 2, which was maintained throughout the trial period.
  • These findings were observed across patient subgroups, including those with severe, long-standing Condition Y.

Research on Long-Term Data

The long-term extension of the RCT evaluated whether patients receiving Concordina showed continued observations regarding quality of life metrics over two years.

In addition, a large meta-analysis compared Concordina to Drug Z (a common older treatment) and examined differences in preventing relapse. Further research is needed to determine whether co-morbidities influence the outcomes observed in comparisons between treatments.


Safety Profile Evaluation

Concordina’s safety profile was evaluated in clinical trials, where studies identified potential side effects.

  • The most common side effects reported were typically mild and transient.
  • Severe side effects are rare, and symptoms like X, Y, or Z have been reported in the research.

Overall, the evidence base indicates that studies of Concordina have examined its use in relation to Condition Y.

Frequently Asked Questions (FAQ)

Common questions about Concordina (FAQ)


Q: What happens if I forget to take Concordina for a day?

According to official product information, if a dose is missed and is remembered soon, it is typically taken immediately. If it is almost time for the next scheduled dose, the missed dose is skipped to maintain the regular schedule. A double dose is not to be taken to compensate for a missed dose.

Q: Can I take pain relievers, like ibuprofen or acetaminophen, while using Concordina?

Regulatory guidance for the bisoprolol component notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the intended blood pressure lowering effects of the medication. This potential for interaction is described in official documentation. Information regarding common pain relievers like acetaminophen is not typically highlighted as a mandatory interaction warning.

Q: Is it true that Concordina is non-habit forming? / Is Concordina a controlled substance?

Studies and official information indicate that the active ingredients in Concordina, Amlodipine and Bisoprolol, are not currently classified as controlled substances. This means the medicine is not subject to the strict regulations of the US Controlled Substances Act (CSA) or similar international drug scheduling systems.

Q: Does Concordina cause weight gain or weight loss?

Weight gain is listed in some regulatory summaries as a less common adverse effect associated with the amlodipine component of the drug. Weight loss is not typically highlighted in the official side effect profile of this medication.

Q: Is Concordina known to affect sleep patterns?

Official adverse event reporting for the components lists sleep-related issues as potential side effects. These reports include issues such as insomnia (difficulty sleeping) and somnolence (drowsiness) as potential side effects. These effects are documented in regulatory summaries of clinical studies.

Q: Is Concordina safe for use by older adults?

The usual doses can generally be administered to older adults. However, official regulatory guidance notes that caution is advised when the dose is increased due to possible age-related differences in how the body processes the medicine. Use is restricted to adult patients (18 and older).

Q: How long does the effect of one dose of Concordina typically last?

The amlodipine component of the fixed-dose combination has a long terminal elimination half-life, typically ranging from 30 to 50 hours. This property is a characteristic of the drug that allows for its once-daily dosing.

Q: Does Concordina interact with birth control pills?

General regulatory guidance on beta-blockers, which includes the bisoprolol component, suggests they are not thought to reduce the effectiveness of hormonal contraceptives. This is based on typical pharmacological evaluations of this drug class.

Q: Can men and women use Concordina in the exact same way?

Clinical trial summaries, which inform regulatory labeling, typically evaluate the effects of the drug in both sexes. The labeling specifies use for adult patients generally without gender-specific differences in dosing or administration instructions.

Q: Is it normal to feel slightly dizzy when first starting Concordina?

Dizziness is listed in the regulatory documentation as a common or less common adverse event for the components of Concordina. This symptom may be particularly noticeable when first starting the medicine, or when changing position, such as moving from sitting or lying down to standing.

Q: Where can I find the official regulatory information about Concordina?

Official patient-friendly information is typically provided through a Patient Information Leaflet (PIL) or Medication Guide. These documents are mandated to accompany the drug's full Prescribing Information (PI) or Summary of Product Characteristics (SmPC) that detail how the medicine is authorized for use.

Q: Does Concordina affect alertness or the ability to drive?

The regulatory labeling includes warnings that the drug may cause adverse effects such as dizziness, headache, or fatigue. These effects could potentially impair the ability to drive or operate machinery, and official warnings advise this consideration.

Q: Are there any known issues with taking Concordina with alcohol?

Regulatory guidance describes risks associated with consuming alcohol while taking the amlodipine component. This may result in dizziness, lightheadedness, or fainting due to additive blood pressure lowering effects.

Q: Why is Concordina sometimes mentioned alongside diet and exercise?

Regulatory guidance for managing high blood pressure generally states that drug treatment is intended to be part of a comprehensive health strategy. This strategy includes recommended lifestyle changes, such as maintaining a healthy diet and regular physical activity, to achieve the most effective outcome.

Q: What are the possible risks of overdose with Concordina?

Risks of overdose, based on the components, include severe issues related to blood pressure and heart function. These issues may include profound hypotension (very low blood pressure), bradycardia (dangerously slowed heart rate), and, in severe cases, shock or cardiac insufficiency.

Q: How long does Concordina stay in the body after the last dose?

The amlodipine component has an elimination half-life typically ranging from 30 to 50 hours. This pharmacokinetic data indicates that it takes several days for the medicine to be completely cleared from the body after the last dose is taken.

Q: Does Concordina affect mood or cause emotional changes?

Some regulatory summaries for the beta-blocker drug class, which includes the bisoprolol component, note that side effects such as depression or changes in mood have been reported in patients. This information is included in the official adverse event profile.

Q: Are there any mandatory patient guidelines or brochures for Concordina?

Yes, official patient-friendly information is typically provided through a Patient Information Leaflet (PIL) or Medication Guide. This material is mandated to accompany the drug's full Prescribing Information or Summary of Product Characteristics to inform the patient.

Q: Can I take other vitamins while on Concordina?

Regulatory documents generally note that caution is advised regarding the co-administration of supplements due to a lack of specific testing on all possible combinations. However, no general interaction is documented for standard daily vitamins in the official labeling.

Q: How does Concordina compare generally to other drugs used for the same condition?

Regulatory reviews of the clinical evidence describe studies comparing the Concordina fixed-dose combination to its individual components when taken separately. The combination showed greater reduction in blood pressure compared to monotherapy in these studies. Additionally, some meta-analyses have examined its use in comparison to other older treatments for hypertension.

Q: Does Concordina have any known long-term effects?

Regulatory safety data reports include known effects observed in trials, which may cover the duration of studies up to two years. The most common side effects are frequently described as transient. Any specific long-term adverse events identified are detailed in the official safety documentation.

Q: Does age or weight influence the effect of Concordina?

Official guidance primarily addresses dose limitations based on age (restricted to adult use) and physiological limitations, such as severe renal or hepatic impairment. However, official product information does not typically define specific dosing adjustments based on body weight alone.

How should Concordina be stored and disposed of?

How to Store and Dispose of Concordina?

The storage and disposal instructions for Concordina (Amlodipine/Bisoprolol Fumarate) are defined by official labeling to maintain product quality and environmental safety.

Storage Requirements

Condition Requirement
Temperature Store below 30 C (thirty degrees Celsius).
Protection Keep protected from moisture and light.
Container Must be stored in the original package (the blister).
Safety Keep the medicine out of the sight and reach of children.

Disposal

Official instructions prohibit disposing of the medicine via wastewater or standard household trash. Unused or expired tablets must be handled as pharmaceutical waste, typically by returning them to a pharmacy or using a community disposal take-back program in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Concordina found in:

A-Z Index: